SAO PAULO - Clinical trials of the CoronaVac coronavirus vaccine developed by Chinese laboratory Sinovac have "reached the efficacy threshold" demanded by the World Health Organization, the Brazilian institute charged with its production and distribution said on Wednesday.
The Butantan Institute, however, didn't publish the results of those trials - the last before authorization.
"We're reached the efficacy threshold that allows us to seek an emergency use" authorization from Brazil's Anvisa regulatory agency, said Butantan director Dimas Covas.
He said a clause in the Sinovac contract insisted that these phase III test results could only be made public once all clinical trials around the world have been completed.
In Brazil, 13,000 volunteers took part in the trials, which were also performed in Turkey, Indonesia and China.
"Our entire program remains unchanged. The production of doses is continuing in our factory and the immunization campaign will begin as expected on January 25," said Sao Paulo state health secretary Jean Gorinchteyn.
Covas said the federal government would order 100 million CoronaVac doses, more than double the 46 million initially publicized.
Brazil has suffered the second largest number of coronavirus deaths in the world after the US with 188,000 dead.